Research Paper

Role of CT texture features for predicting outcome of pancreatic cancer patients with liver metastases

Junjie Hang1#, Kequn Xu1#, Ruohan Yin2#, Yueting Shao1, Muhan Liu1, Haifeng Shi2,### Xiaoyong Wang3,### and Lixia Wu4,###

1. Department of Oncology, Changzhou No.2 People’s Hospital, Nanjing Medical University, Xinglong Road 19, Changzhou 213000, China.
2. Department of Medical Imaging, Changzhou No.2 People’s Hospital, Nanjing Medical University, Xinglong Road 19, Changzhou 213000, China.
3. Department of Gastroenterology, Changzhou No.2 People’s Hospital, Nanjing Medical University, Xinglong Road 19, Changzhou 213000, China.
4. Department of Oncology, Shanghai JingAn District ZhaBei Central Hospital, Zhonghuaxin Road 619, Shanghai 200040, China.

#These authors contributed equally to this work.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.06.16; Accepted: 2021.01.13; Published: 2021.02.22

Abstract

Objective: The purpose of this study was to evaluate the prognostic value of computed tomography (CT) texture features of pancreatic cancer with liver metastases.

Methods: We included 39 patients with metastatic pancreatic cancer (MPC) with liver metastases and performed texture analysis on primary tumors and metastases. The correlations between texture parameters were assessed using Pearson’s correlation. Univariate Cox proportional hazards model was used to assess the correlations between clinicopathological characteristics, texture features and overall survival (OS). The univariate Cox regression model revealed four texture features potentially correlated with OS (P<0.1). A radiomics score (RS) was determined using a sequential combination of four texture features with potential prognostic value that were weighted according to their β-coefficients. Furthermore, all variables with P<0.1 were included in the multivariate analysis. A nomogram, which was developed to predict OS according to independent prognostic factors, was internally validated using the C-index and calibration plots. Kaplan-Meier analysis and the log-rank test were performed to stratify OS according to the RS and nomogram total points (NTP).

Results: Few significant correlations were found between texture features of primary tumors and those of liver metastases. However, texture features within primary tumors or liver metastases were significantly associated. Multivariate analysis showed that Eastern Cooperative Oncology Group performance status (ECOG PS), chemotherapy, Carbohydrate antigen 19-9 (CA19-9), and the RS were independent prognostic factors (P<0.05). The nomogram incorporating these factors showed good discriminative ability (C-index = 0.754). RS and NTP stratified patients into two potential risk groups (P<0.01).

Conclusion: The RS derived from significant texture features of primary tumors and metastases shows promise as a prognostic biomarker of OS of patients with MPC. A nomogram based on the RS and other independent prognostic clinicopathological factors accurately predicts OS.

Key words: CT texture features; liver metastases; pancreatic cancer; prognostic nomogram; radiomics score

Introduction

Pancreatic cancer is the seventh leading cause of cancer-related death worldwide, and its incidence closely parallels mortality [1]. Approximately 53% of patients with pancreatic cancer present with metastatic disease upon initial diagnosis [2]. The liver is one of the most common metastatic sites of pancreatic cancer, and patients with MPC with liver metastases experience much poorer prognosis than those with other metastatic patterns [3]. Although a small portion of patients with MPC can benefit in OS
from targeted therapy and immunotherapy, cytotoxic chemotherapy remains the mainstay of treatment [4]. As we move towards an era of precision medicine, more information about the tumor facilitates decision-making that will improve patients’ outcomes.

CT is routinely used in the diagnosis and efficacy evaluation of pancreatic cancer with size-based or shape-based measures of the tumor [5, 6]. However, the information acquired from CT is limited, because it mainly relies upon visual evaluations. Fortunately, recent research shows that the interpretations of CT images are augmented by texture analysis, which potentially reveals the underlying tumor biology [7]. Texture analysis of CT involves a computational process in which weakening CT levels among image voxels are spatially quantified to associate structural features of tumors with pixel variability [8]. The histogram-based method and spatial arrangement-based methods are most frequently used for texture analysis, and the corresponding texture features are evaluated using first-order statistics and higher-order statistics [9]. These methods are applied for detection, characterization, and monitoring of tumors [7, 10].

The texture features of pancreatic cancer facilitate diagnosis and treatment effect prediction. For example, texture analysis differentiates pancreatic adenocarcinoma from other pancreatic lesions such as pancreatic neuroendocrine carcinoma, mass-forming pancreatitis, and pancreatic lymphoma [11-13]. Certain CT texture features, such as tumor dissimilarity and kurtosis, were significantly correlated with OS of patients with pancreatic cancer [14-17]. Furthermore, Marc A. Attiyeh et al. found CT texture features were associated with SMAD4 status and stromal content in pancreatic cancer [18]. In addition, texture features may play a role in predicting the responses of patients to chemotherapy [19, 20]. However, to the best of our knowledge, there is paucity of studies about the potential prognostic value of CT texture features of primary tumors and liver metastases of pancreatic cancer. The aim of this study therefore was to determine their value in predicting the survival of MPC patients with liver metastases.

Methods

Patients

39 consecutive MPC patients with liver metastases treated at Changzhou No. 2 People’s Hospital between January 2016 and June 2019 were retrospectively enrolled in this study. The inclusion criteria were as follows: (1) newly diagnosed, and pathologically confirmed pancreatic adenocarcinoma, (2) absence of concurrent cancer at another site, and (3) availability of complete records of baseline clinicopathological features. Demographic and clinicopathological features were collected from the electronic medical record. Informed consent was obtained from each patient and ethical approval was obtained by the Ethics Committee of Changzhou No.2 People’s Hospital.

CT image acquisition

Contrast-enhanced CT examinations were performed using a 128-row dual-source CT scanner (SOMATOM Definition Flash, Siemens, Germany) at 120 kV, tube current modulation, and 1 mm reconstructed section thickness. All patients were instructed to fast for at least 8 h before the administration of intravenous contrast (Iohexol, 300 mg/ml, 80 ml, at a rate of 3 ml/s). After the injection of contrast agent, patients were subsequently subjected to double-helical scanning during the arterial and portal venous phases. The region of interest (ROI) was selected during the portal venous phase, because margins of pancreatic cancers are most consistently detected during in this phase.

Image processing

ROIs were drawn on each slice of the primary pancreatic cancer and the liver metastases, using the Semantic Segmentation Editor. ROIs were subsequently extracted for texture analysis using Local Image Features Extraction (LIFEx, version 5.10, https://www.lifexsoft.org/). In the segmented tumors, the volume of interest (VOI) and histogram were calculated as first-order features. For calculations of second- and high-order texture features, the number of grey levels used to resample the ROI content was set to 64.0 as described in previous studies. The Cartesian coordinates for spatial resampling were 2.0 mm (X-direction), 2.0 mm (Y-direction), and 1.0 mm (Z-direction). Texture features were evaluated using four texture matrices, including the grey-level co-occurrence matrix (GLCM), the grey-level run length matrix (GLRLM), the neighborhood grey-level different matrix (NGLDM), and the grey-level zone length matrix (GLZLM). The texture features of the largest cross-section of each tumor and its corresponding liver metastases were used for further analysis.

Statistical analysis

Statistical analysis was conducted using R software (version 3.6.1, Institute for Statistics and Mathematics, Vienna, Austria). The correlations between texture variables were assessed using Pearson’s correlation coefficient with the R package “psych”. A univariate Cox regression model was used to assess the correlations between clinicopathological...
characteristics, texture features, and OS. A radiomics score (RS) was calculated according to the results of univariate analysis, where RS = 0.280 × tGLZLM_LZE + 0.337 × tGLZLM_LZHGE + 0.334 × lKurtosis + 0.364 × INGLDM_Busyness. In this formula, each variable was weighted using its \( \beta \)-coefficient derived from the Cox regression model. Variables with \( P < 0.1 \) were included in the multivariate analysis. A nomogram was weighted according to their \( \beta \)-coefficient derived from the Cox regression model. Variables with \( P < 0.1 \) were included in the multivariate analysis. A nomogram was weighted using “rms”. The internal validation of the nomogram was performed using the C-index and a calibration plot generated using bootstrapping with 1000 resamples. Kaplan Meier analysis and the log-rank test were performed to stratify OS according to groups of RS and nomogram total points (NTP).

Results

Patients’ characteristics

The baseline clinicopathological characteristics of patients with MPC are listed in Table 1. The patients included 16 (41.0%) women and 23 (59.0%) men, and 79.5% (n=31) of them had ECOG PS = 2 or 3, and 8 (20.5%) had ECOG PS = 1. Among the 23 (59.0%) patients with MPC, the lesions were in the body and tail of the pancreas, whereas among 16 (41.0%) patients, the lesions were in the head and neck. Furthermore, 9 (23.1%) patients had one site of liver metastasis, and 30 (76.9%) patients had >1 site. The mean of the longest diameters of liver metastases was 3.1 cm (SD = 2.7). Among all patients, 14 (35.9%) received combination therapy, 13 (33.3%) received monotherapy, and 12 (30.8%) patients received only best support care (BSC).

Texture analysis

The mean values and standard deviations of all texture features are listed in Supplementary Table 1, and the values of these features were normalized for further analysis.

Pearson’s correlation coefficient was used to investigate the correlations between texture features listed in Supplementary Table 2 to 4. Intriguingly, we found that the texture features within the primary tumor (mean \( r = 0.444 \), Figure 1A) or liver metastases (mean \( r = 0.444 \), Figure 1B) significantly correlated with each other, and some had similar correlation patterns (like those within the yellow box). However, few significant correlations were found between texture features of the primary tumor and those of liver metastases (mean \( r = 0.119 \), Figure 1C). For example, the GLZLM_LGZE of the primary tumor (tGLZLM_LGZE) was significantly correlated with the GLRLM_LGRE of the primary tumor (tGLRLM_LGRE) \( (r = 0.959) \). Likewise, the GLZLM_LGZE of the liver metastases (lGLZLM_LGZE) was also significantly correlated with the GLRLM_LGRE of the liver metastases (lGLRLM_LGRE) \( (r = 0.949) \). However, the correlation between tGLZLM_LGZE and lGLRLM_LGRE was not significant \( (r = -0.082) \). Such phenomenon can also be seen in other pairs such as GLRLM_HGRE and GLZLM_HGZE.

Table 1. Baseline clinicopathological characteristics of patients

| Characteristics          | Mean ± SD          | 95%CI       | \( P \) |
|--------------------------|--------------------|------------|--------|
| Age (year)               | 66.5±31.2          |            |        |
| Gender                   | Male 23 (39.0%)    |            |        |
|                          | Female 16 (41.0%)  |            |        |
| ECOG PS                  | 1 8 (20.5%)        | 31 (79.5%) |        |
| 2 or 3                   | 31 (79.5%)         |            |        |
| Hypertension             | Yes 16 (41.0%)     |            |        |
|                          | No 23 (59.0%)      |            |        |
| Diabetes                 | Yes 9 (23.1%)      |            |        |
|                          | No 30 (76.9%)      |            |        |
| Primary tumor location   | Head and neck 16 (41.0%) |            |        |
|                          | Body and tail 23 (59.0%) |            |        |
| Abdominal pain           | Yes 29 (74.4%)     |            |        |
|                          | No 10 (25.6%)      |            |        |
| Weight loss              | Yes 6 (15.4%)      |            |        |
|                          | No 33 (84.6%)      |            |        |
| Chemotherapy             | Combination therapy 14 (35.9%) |            |        |
|                          | Monotherapy 13 (33.3%) |            |        |
|                          | None 12 (30.8%)    |            |        |
| CEA (ng/ml)              | Mean ± SD 60.6±145.7 |            |        |
| CA19-9 (U/ml)            | Mean ± SD 556.9±440.1 |            |        |
| Number of liver metastases | 1 9 (23.1%) |            |        |
|                          | >2 30 (76.9%)      |            |        |
| Longest diameter of liver metastases | Mean ± SD 3.1±2.7 |            |        |

Table 2. Univariate analysis of prognostic texture features for OS

| Characteristics          | \( \beta \) | HR 95%CI          | \( P \) |
|--------------------------|------------|-------------------|--------|
| tGLZLM_LZE               | 0.280      | 1.324 (0.954-1.836) | 0.093  |
| tGLZLM_LZHGE             | 0.337      | 1.401 (0.979-2.005) | 0.065  |
| lKurtosis                | 0.334      | 1.396 (0.992-1.964) | 0.055  |
| INGLDM_Busyness          | 0.364      | 1.439 (1.028-2.013) | 0.034  |

The prognostic significance of the RS

In the univariate Cox regression model, four texture features were significantly correlated with OS (\( P < 0.1 \), Table 2). The RS was determined using a sequential combination of these four features weighted according to their \( \beta \)-coefficients. Univariate analysis revealed that age, ECOG PS, weight loss, chemotherapy, CA19-9, the longest diameter of liver metastases, and the RS were correlated with OS. Furthermore, multivariate analysis showed that ECOG PS, chemotherapy, CA19-9, and the RS were independent prognostic factors for OS (each, \( P < 0.05 \), Table 3).

A nomogram developed incorporating these independent prognostic factors (Figure 2) predicted the median OS and survival probabilities of patients with MPC at 3-month, 6-months, 9-months and 2353
Table 3. Univariate and multivariate analysis of prognostic factors for OS

| Characteristics                  | Univariate analysis | Multivariate analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | HR                  | 95% CI                | P        | HR                  | 95% CI                | P        |
| Age                              | 1.027               | 0.998-1.057           | 0.073    | 1.028               | 0.992-1.066           | 0.126    |
| Gender                           | Ref                 |                       |          | Ref                 |                       |          |
| Male                             | 0.830               | 0.426-1.619           | 0.586    | 0.251               | 0.064-0.985           | 0.048    |
| Female                           | Ref                 |                       |          | Ref                 |                       |          |
| ECOG PS                          | Ref                 |                       |          | Ref                 |                       |          |
| <2                               | 0.149               | 0.044-0.503           | 0.002    | 0.251               | 0.064-0.985           | 0.048    |
| ≥2                               | Ref                 |                       |          | Ref                 |                       |          |
| Hypertension                     | Ref                 |                       |          | Ref                 |                       |          |
| Yes                              | 1.112               | 0.799-1.548           | 0.529    | Ref                 |                       |          |
| No                               | Ref                 |                       |          | Ref                 |                       |          |
| Diabetes                         | Ref                 |                       |          | Ref                 |                       |          |
| Yes                              | 1.29                | 0.875-1.901           | 0.198    | Ref                 |                       |          |
| No                               | Ref                 |                       |          | Ref                 |                       |          |
| Primary tumor location           | Ref                 |                       |          | Ref                 |                       |          |
| Head and neck                    | 1.046               | 0.542-2.017           | 0.894    | Ref                 |                       |          |
| Body and tail                    | Ref                 |                       |          | Ref                 |                       |          |
| Abdominal pain                   | Ref                 |                       |          | Ref                 |                       |          |
| Yes                              | 1.139               | 0.777-1.669           | 0.504    | Ref                 |                       |          |
| No                               | Ref                 |                       |          | Ref                 |                       |          |
| Weight loss                      | Ref                 |                       |          | Ref                 |                       |          |
| Yes                              | 2.671               | 1.083-6.592           | 0.033    | 1.032               | 0.324-3.283           | 0.957    |
| No                               | Ref                 |                       |          | Ref                 |                       |          |
| Chemotherapy                     | Ref                 |                       |          | Ref                 |                       |          |
| Combination therapy              | 0.214               | 0.086-0.533           | 0.001    | 0.260               | 0.092-0.732           | 0.011    |
| Monotherapy                      | 0.284               | 0.116-0.696           | 0.006    | 0.206               | 0.075-0.562           | 0.002    |
| None                             | Ref                 |                       |          | Ref                 |                       |          |
| CEA (ng/ml)                      | Ref                 |                       |          | Ref                 |                       |          |
| <5                               | 1.262               | 0.648-2.461           | 0.494    | Ref                 |                       |          |
| ≥5                               | Ref                 |                       |          | Ref                 |                       |          |
| CA19-9 (U/ml)                    | Ref                 |                       |          | Ref                 |                       |          |
| <1000                            | 0.330               | 0.152-0.714           | 0.005    | 0.310               | 0.124-0.775           | 0.012    |
| ≥1000                            | Ref                 |                       |          | Ref                 |                       |          |
| Number of liver metastases      | Ref                 |                       |          | Ref                 |                       |          |
| 1                                | 0.773               | 0.357-1.675           | 0.514    | Ref                 |                       |          |
| ≥2                               | Ref                 |                       |          | Ref                 |                       |          |
| Longest diameter of liver metastases | 1.125                | 0.982-1.288           | 0.089    | 0.862               | 0.715-1.039           | 0.119    |
| Radiomics score                  | 2.453               | 1.483-4.055           | <0.001   | 3.193               | 1.474-6.917           | 0.003    |

Discussion

In this study, we used texture analysis to evaluate CT images of primary tumors and liver metastases of patients with MPC. We showed that the RS of significant texture features was an independent prognostic factor of OS, as revealed by univariate analysis. A nomogram, which was based on RS and other independent prognostic clinicopathological factors, achieved good discriminative ability.

In univariate analysis, GLZLM_LZE and GLZLM_LZHGE of the primary tumor, as well as Kurtosis and NGLDM_Busyness of liver metastases, showed potential correlations with survival. Briefly, GLZLM reflects the size of homogeneous zones for each grey-level in three dimensions. LZE and LZHGE represent the distribution of the long homogeneous zones and its high grey-level subtypes, respectively. Furthermore, kurtosis reflects the shape of the grey-level distribution in the ROI. NGLDM_Busyness provides information on the spatial frequency of three-dimensional changes in intensities of grey-level between one voxel and its corresponding 26 neighbors. Generally, higher levels of these parameters reflect increased histological heterogeneity of the tumor and metastases, which will lead to poor prognosis of patients.

Several studies have reported the prognostic value of CT texture features for pancreatic cancer. For example, in patients with resectable pancreatic cancer patients, normalized dissimilarities and inverse difference serve as independent prognostic biomarkers of OS [14]. Similarly, quantification of imaging features could predict survival when combined with CA19-9 levels of patients with pancreatic cancer who undergo resection [21]. Furthermore, the texture feature of CT images facilitates predicting OS in conjunction with the expression of HMGA2 and C-MYC in pancreatic cancer [22]. More recent studies show that the prognosis of patients with locally advanced pancreatic cancer patients who undergo stereotactic body radiation, can be predicted according to the mean value, GLCM_Homogeneity, standard deviation value and GLCM_Dissimilarity of texture features [23]. In patients with unresectable pancreatic cancer, Sandrasegaran et al found that the mean positive pixel value determined using a medium spatial filter was significantly associated with OS [15]. In addition, Cheng et al found the tumor standard deviation was independently correlated with progression-free survival (PFS) and OS, while skewness was independently associated with PFS [16].

Here we show that the RS derived from the four aforementioned texture features was independently correlated with OS of patients with MPC with liver metastases. Furthermore, the nomogram, based on the RS, CA19-9, ECOG PS, and chemotherapy, achieved sufficient discriminative ability (C-index: 0.754), which was significantly higher compared with that of
a model that did not incorporate RS (C-index: 0.712). These results suggest that the texture features of CT images play a pivotal role in predicting the outcome of patients with MPC with liver metastases.

Figure 1. The correlations between texture parameters. The correlations between texture parameters within primary pancreatic cancer (A) or within liver metastases (B) were relatively significant (mean $r = 0.444$), and some had similar correlation patterns (like those within the yellow box). However, few significant correlations were found between texture features of the primary tumor and those of liver metastases (mean $r = 0.119$, C).
Figure 2. Prognostic nomogram for predicting 3-, 6-, 9-, and 12-month overall survival probability based on ECOG PS, liver metastases, CA19-9, and radiomics scores in pancreatic cancer patients with liver metastases. Each status of 4 independent factors has a corresponding value to the “Points” line at the top of the scale. Then the total point score was calculated by summing these 4 “Points” values. Based on the score, draw a downward vertical line from the “Total Points” line, predicting 3-, 6-, 9-, and 12-month survival probability in a given patient.

Figure 3. Calibration curves of the nomogram for the prediction of 3-month survival. The diagonal line: the ideal calibrated model. Black line: actual calibration. Circles: median. X: mean. 95% confidence intervals are depicted for each point along the calibration curve.

The limitations of our study include its relatively small sample size and relatively wider range of texture features, which may introduce bias. Furthermore, patients received different types of chemotherapy or BSC. The heterogeneity of treatment strategies may influence the outcome, although we included this variable in multivariate analysis. Moreover, the use of the regions encompassing the largest cross-section of the tumor and its corresponding liver metastases may not comprehensively reflect the lesion, because of intrinsic tumor heterogeneity. Independent cohorts are therefore required to externally validate our results, along with the demonstration of the reproducibility and prognostic value of these texture features.

In conclusion, the RS based on texture features of the primary tumor and liver metastases shows promise as a prognostic imaging biomarker for patients with MPC with liver metastases. The nomogram developed here incorporating the RS and prognostic clinicopathological valuables will serve to accurately predict the outcomes of patients with pancreatic cancer.

Abbreviations
CT: computed tomography; MPC: metastatic pancreatic cancer; OS: overall survival; RS: radiomics score; NTP: nomogram total points; ECOG PS: Eastern Cooperative Oncology Group performance status; CA19-9: Carbohydrate antigen 19-9; ROI: region of interest; VOI: volume of interest; GLCM: grey-level co-occurrence matrix; GLRLM: grey-level run length matrix; NGLDM: neighborhood grey-level different matrix; GLZLMD: grey-level zone length matrix; BSC: best support care; tGLZLMD_LGZE: GLZLMD_LGZE of the primary tumor; tGLRLM_LGRE: GLRLM_LGRE of the primary tumor; lGLZLMD_LGZE: GLZLMD_LGZE of the liver metastases; lGLRLM_LGRE: GLRLM_LGRE of the liver metastases; PFS: progression-free survival.

Supplementary Material
Supplementary tables.
http://www.jcancer.org/v12p2351s1.xlsx

Acknowledgements
This work was supported by grants from the
National Natural Science Foundation of China (81902955), the Natural Science Foundation of Jiangsu Province (BK20190161), Project of Jiangsu Shuangchuang Doctor (QT201904), Foundation of Changzhou Sci & Tech Program (CJ20190096), the Youth Science and Technology Project of Changzhou Health and Family Planning Commission (QN201817), the Young medical talents of Jiangsu province (QNR2016269), the High-level Medicine Talents Training Project (2016CZBJ022), Changzhou International Science and Technology Cooperation Project (CZZ20190021).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018; 68(6):394-424.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA: a cancer journal for clinicians. 2020; 70(1):7-30.
3. Hang J, Wu L, Zhu L, et al. Prediction of overall survival for metastatic pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real-world study. Cancer medicine. 2018; 7(7):2974-2984.
4. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer: Development and validation of a prognostic nomogram with data from open clinical trial and real-world study. Cancer medicine. 2018; 7(7):2974-2984.
5. Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. Nature reviews Clinical oncology. 2020; 17(2):108-123.
6. Tamn EP, Bhosale PR, Lee JH. Pancreatic ductal adenocarcinoma: ultrasound, computed tomography, and magnetic resonance imaging features. Seminars in ultrasound, CT, and MR. 2007; 28(5):330-338.
7. Grenacher L, Krauss M. Computed tomography of pancreatic tumors. Der Radiologe. 2009; 49(2):107-123.
8. Bi WL, Honya A, Schabath MB, et al. Artificial intelligence in cancer imaging: Clinical challenges and applications. CA: a cancer journal for clinicians. 2019; 69(2):127-157.
9. Mungai F, Verrone GB, Pietragalla M, et al. CT assessment of tumor heterogeneity and the potential for the prediction of human papillomavirus status in oropharyngeal squamous cell carcinoma. La Radiologia medic. 2019; 124(9):804-811.
10. Nioche C, Orliac F, Bouhdad S, et al. LIFE: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer research. 2018; 78(16):4786-4789.
11. Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive radiomics using a quantitative radiomics approach. Nature communications. 2014; 5:4006.
12. Guo C, Zhuo X, Wang Q, et al. The differentiation of pancreatic neuroendocrine carcinoma from pancreatic ductal adenocarcinoma: the values of CT imaging features and texture analysis. Cancer imaging: the official publication of the International Cancer Imaging Society. 2018; 18(1):37.
13. Ren S, Zhang J, Chen J, et al. Evaluation of Texture Analysis for the Differential Diagnosis of Mass-Forming Pancreatitis From Pancreatic Ductal Adenocarcinoma on Contrast-Enhanced CT Images. Frontiers in oncology. 2019; 9:1171.
14. Huang Z, Li M, He D, et al. Two-dimensional Texture Analysis Based on CT Images to Differentiate Pancreatic Lymphoma and Pancreatic Adenocarcinoma: A Preliminary Study. Academic radiology. 2019; 26(8):e189-e195.
15. Ilaghi A, Baig S, Zhang Y, et al. CT texture features are associated with overall survival in pancreatic ductal adenocarcinoma - a quantitative analysis. BMC medical imaging. 2017; 17(1):38.
16. Sandrasegaran K, Lin Y, Asare-Sawiri M, et al. CT texture analysis of pancreatic cancer. European radiology. 2019; 29(3):1067-1073.
17. Cheng SH, Cheng YJ, Jin ZY, et al. Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy. European journal of radiology. 2019; 113:188-197.
18. Kim HS, Kim YJ, Kim KG, et al. Preoperative CT texture features predict prognosis after curative resection in pancreatic cancer. Scientific reports. 2019; 9(1):17389.
19. Attiyeh MA, Chakraborty J, McIntyre CA, et al. CT radiomics associations with genotype and stromal content in pancreatic ductal adenocarcinoma. Abdominal radiology (New York). 2019; 44(9):3148-3157.
20. Kaissis G, Ziegelmayer S, Lohöfer F, et al. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy. PloS one. 2019; 14(10):e0218642-e0218642.
21. Attiéyeh MA, Chakraborty J, Doussot A, et al. Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis. Ann Surg Oncol. 2018; 25(4):1034-1042.
22. Li K, Xiao J, Yang J, et al. Association of radiomic imaging features and gene expression profile as prognostic factors in pancreatic ductal adenocarcinoma. Am J Transl Res. 2019; 11(7):4491-4499.

23. Cozzi L, Comito T, Fogliata A, et al. Computed tomography based radiomic signature as predictive of survival and local control after stereotactic body radiation therapy in pancreatic carcinoma. PloS one. 2019; 14(1):e0210758-e0210758.